Top 5 Key Players companies in PCSK9 Inhibitors by Most Patent Filings in the United States in 2022 – Discovery

Free Trial

The PCSK9 Inhibitors top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filings PCSK9 Inhibitors Key Players in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.

Ranking Year:

Region:

Ranking:

1	Regeneron Pharmaceuticals, Inc.	New York, United States	Monoclonal antibody,Clinical trial,Cholesterol, ...[+2]	Patent: 188
2	Amgen, Inc.	California, United States	Health care,Biopharmaceutical,TUMOR NECROSIS FACTOR BLOCKER, ...[+2]	Patent: 16
3	CymaBay Therapeutics, Inc.	California, United States	Drug,Gout,Drug development, ...[+2]	Patent: 15
4	Ra Pharmaceuticals, Inc.	Massachusetts, United States	Medicine,Health care,Drug class, ...[+2]	Patent: 3
5	STARTUP Dogma Therapeutics, Inc.	Massachusetts, United States	PCSK9,Cardiovascular agent,Biophysics, ...[+2]	Patent: 3